NCT04810793

The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 820 (actual)
• Sponsor: Shandong University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Detailed description

Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment in patients with Hp eradication failure.

Conditions

• Helicobacter Pylori

Interventions

Type	Name	Description
DRUG	Amoxicillin , Levofloxacin and Esomeprazole	Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
DRUG	Amoxicillin , Furazolidone and Esomeprazole	Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
DRUG	Tetracycline , Furazolidone and Esomeprazole	Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
DRUG	Amoxicillin,Levofloxacin and Vonoprazan fumarate	Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
DRUG	Amoxicillin,Furazolidone and Vonoprazan fumarate	Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
DRUG	Tetracycline,Furazolidone and Vonoprazan fumarate	Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group

Timeline

• Start date: 2020-07-01
• Primary completion: 2022-06-01
• Completion: 2022-06-30
• First posted: 2021-03-23
• Last updated: 2022-10-27

Locations

1 site across 1 country: China